UK-Based Company, 32Co, Expands Comprehensive Sleep Centre Network Nationwide to Address Escalating Sleep Disorder Predicament
32Co Expands Aerox Sleep Centres Across the UK, Revolutionising Obstructive Sleep Apnea Treatment
London-based healthtech company 32Co is set to revolutionise the treatment of obstructive sleep apnoea (OSA) and problematic snoring in the UK with the launch of its nationwide network of sleep centres, named 'Aerox Sleep Centres'. This summer will see the opening of pilot centres in London, Manchester, Edinburgh, and Bristol, with new centres planned across the country.
The Aerox Sleep Centres are designed to provide accessible treatment for those suffering from mild to moderate OSA and problematic snoring. By integrating these sleep centres within dental practices, 32Co aims to address the limited patient access to OSA treatment, offering convenient localised care and a curated marketplace for custom-made devices like Mandibular Advancement Splints (MADs).
The expansion of Aerox Sleep Centres marks 32Co’s entrance into a second healthcare vertical beyond orthodontics. Leveraging its existing network, where 90% of the UK population is within 20 minutes of a 32Co dentist, the company is poised to make a significant impact on the UK sleep disorder treatment market.
To ensure the success of this initiative, 32Co is upskilling dentists in OSA treatment, giving them access to medical specialists for virtual collaboration and creating a market for MADs. This approach has been well-received, with 80% of the patients 32Co spoke to admitting they would be very disappointed if they could no longer use their sleep devices.
Helen, a 64-year-old London resident, believes that many people would benefit from MADs as they are unobtrusive. John, a 69-year-old from Manchester, stated that he would be back sleeping downstairs with the dog if his device broke. These sentiments echo the findings of pre-pilot trials, which show that the Aerox Sleep Centres and MADs have helped hundreds of patients improve their sleep.
The industry standard treatment method against sleep apnoea is via Continuous Positive Airway Pressure (CPAP) machines. However, many patients find these machines uncomfortable, claustrophobic, and difficult to travel with. MADs serve as an alternative, with patients typically using MADs for 6.5 hours per night compared to CPAP machines at 5.2 hours per night, indicating 25% higher adherence for MADs.
Snoring contributes to a major cultural shift known as 'sleep divorces', with 19% of millennials and 14% of Gen Z sleeping in another room consistently due to sleep issues. Chronic sleep disruption, linked to depression, memory loss, diabetes, and fatigue-related accidents, can result from untreated sleep disorders. However, with the launch of the Aerox Sleep Centres, patients can look forward to improved sleep and a better quality of life.
In summary, 32Co’s Aerox Sleep Centres program combines market expansion with professional development, making OSA treatment more accessible while enhancing dental practitioners' capabilities in managing sleep-related breathing disorders across the UK. By improving patient access, reducing treatment delays, and increasing multidisciplinary collaboration between dentists and sleep medicine specialists, 32Co is set to transform the UK sleep disorder treatment market.
[1] 32Co Press Release, [link to press release] [2] British Sleep Society, [link to British Sleep Society article]
